The groundbreaking success of Sildenafil undeniably reshaped the medication landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. Despite early returns were substantial, the cessation of patents and the appearance of cheaper alternatives have weakened the customer base. Consequently, a thoroug